Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qsam Biosciences Inc (OP: QSAM )

4.800 +0.025 (+0.52%)
Streaming Delayed Price Updated: 3:32 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qsam Biosciences Inc

< Previous 1 2 Next >
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Adds Clinical Trial Site for CycloSam(R) Study
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Inks Supply Agreement with Leading Nuclear Medicine Pharmacy Network
Via Investor Brand Network
Topics Economy
Exposures Product Safety Supply Chain
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Granted European Patent for Clinical-Stage Radiopharmaceutical Drug Candidate
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Researchers Develop Wireless Implant to Kill Cancer Cells in Brain Tumors
Via Investor Brand Network
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Phase 1 CycloSam(R) Study Ready to Open Cohort 2 Enrollment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) to Provide Clinical Trial Updates at Emerging Growth Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Receives FDA Clearance to Expand Enrollment Criteria in Phase 1 Study of CycloSam(R)
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Featured in New Goldman Small Cap Research Report
Via Investor Brand Network
Exposures Product Safety
Goldman Small Cap Research Publishes New Research Report on QSAM Biosciences, Inc.
Via ACCESSWIRE
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Completion of Enrollment for Phase 1 CycloSam Study
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – QSAM Biosciences Inc. (QSAM) Adds New Trial Site to Expand Study of CycloSam(R) for Bone Cancer
Via Investor Brand Network
Exposures Product Safety
Global Clinical Guidelines to Prevent, Manage Cardiac Complications Among Pediatric Cancer Patients Published
Via Investor Brand Network
Study Finds Mucus-Eating Gut Bacteria May Cause Fever Following Cancer Treatment
Via Investor Brand Network
BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) to Present at Emerging Growth Conference
Via Investor Brand Network
Exposures Product Safety
Stem Cell Therapy Holds Promise in Future Cancer Care
Via Investor Brand Network
Topics Death
Exposures Death
Study Finds Pharmacotyping Pediatric Leukemia Offers Blueprint to Better Precision Medicine
Via Investor Brand Network
TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals
Via Investor Brand Network
Topics Economy
Exposures Product Safety Supply Chain
New Treatment Approach for Cancer Combines Bacterial, Pharmaceutical Therapy
Via Investor Brand Network
Topics Death
Exposures Death
Research Suggests That Vegetarian Diets Decrease Prostate Cancer Risk
Via Investor Brand Network
Trial Shows CAR-T Cells May Be Effective in Treating Brain, Spinal Cord Lymphoma
Via Investor Brand Network
Doing Crossword Puzzles Helps Sharpen Memory Better Than Computer Games
Via Investor Brand Network
Research Discovers That Survivors of Pediatric Cancer Are Prone to Premature Aging
Via Investor Brand Network
Type 2 Diabetes Patients Are Diagnosed Late If They Develop Cancer
Via Investor Brand Network
Cancer Care Adhering to Guidelines Could Help Reduce Treatment Disparities
Via Investor Brand Network
BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Q3 2022 Results, Provides Corporate Update
Via Investor Brand Network
Exposures Product Safety
QSAM Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From QSAM Biosciences Inc.
Via GlobeNewswire
New Discovery May Improve Prospects for Patients with Cancer
Via Investor Brand Network
Study Finds Epigenetics May Revolutionize Treatment of Cancer
Via Investor Brand Network
BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Announces Approval of Second Clinical Trial Site for Phase 1 Study
Via Investor Brand Network
Exposures Product Safety
QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer
From QSAM Biosciences Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.